Cancer Immunotherapy News and Research

RSS

AlphaFold3 reveals molecular interactions driving T cell recognition

Researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, have developed a new approach using the artificial intelligence platform AlphaFold3 to predict whether a T cell receptor will recognize a specific antigen based solely on its genetic sequence.

3 Nov 2026

Researchers find simple way to boost engineered T-cell therapies

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.

29 Oct 2026

Mutated neutrophils may trigger immune attacks in lupus

Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.

28 Oct 2026

Dual-targeting antibody successfully tackles multiple tumor types in mice

A novel antibody therapy empowers the immune system's tumor-fighting capabilities in mice by targeting immune-suppressing T cells with greater precision than previous approaches, according to new work.

28 Oct 2026

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

26 Oct 2026

Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.

24 Oct 2026

Unstable immune cells linked to severe cancer immunotherapy side effects

Scientists at the University of Pittsburgh uncovered the unstable immune cells that can cause up to 40% of immunotherapy patients to experience serious side effects and showed that diet and microbiome composition influence the side effect's severity.

22 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

CSHL researchers find way to make immunotherapy effective against colorectal cancer

Colorectal cancer has become the leading cause of cancer-related death for people under 50. Its most common forms generally aren't treatable, either through conventional means like chemotherapy or newer immunotherapy drugs.

14 Oct 2026

New review highlights expanding potential of therapeutic DNA vaccines

A new review published in Genes & Diseases highlights the expanding potential of DNA-based vaccines as a flexible platform for preventing infectious diseases, treating cancer and strengthening preparedness for future disease outbreaks.

12 Oct 2026

Polymeric nanomedicine strategies improve solid tumor immunotherapy outcomes

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM).

9 Oct 2026

Study explains why cancer immunity declines faster in males

Lutz Menzel, PhD, formerly of the Department of Radiation Oncology within the Mass General Brigham Cancer Institute, and Tim Padera, PhD, currently of the Mass General Brigham Cancer Institute, are the lead and senior authors of a paper published in Nature Aging, "Lymph node contraction links sex-biased naive CD8 T cell decline to compromised antigen recognition during middle age."

9 Oct 2026

Phage proteases activate bacterial immune response to viral infection

In the fight to find better treatments for bacterial infections, one rapidly evolving therapy is a group of viruses called bacteriophages (phages). Phages can attack and kill dangerous bacteria while leaving human cells unharmed and bypassing antibiotic resistance.

1 Oct 2026

Blood tests can identify cancer neoantigens for personalized immunotherapy

Cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells, respectively, and they largely matched those found through traditional tumor tissue biopsy in many patients.

29 Sep 2026

Scientists find new way to overcome cell’s natural defenses against self-amplifying mRNA vaccines

The innovation could enable protection at lower doses, meaning vaccines could be rolled out further and faster than was previously imaginable, and opens new possibilities in gene therapy, cancer immunotherapy, and protein replacement therapies.

28 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026